RNS Number : 9152N
CT Private Equity Trust PLC
28 November 2024
 

 

 

To: Stock Exchange

For immediate release:


28 November 2024

 

CT Private Equity Trust PLC

Quarterly results for the three months ended 30 September 2024 (unaudited)
 

·    Net asset value of 680.03p per Ordinary Share reflecting a total return for the three months of -1.0 per cent for the Ordinary Shares

·    Share price total return for the three-month period of 6.6%.

·    Total quarterly dividends of 21.03p per Ordinary Share year to date representing an increase of 3.3 per cent from the same period last year.

Quarterly dividend of 7.01p paid on 31 July 2024

Quarterly dividend of 7.01p paid on 31 October 2024

Quarterly dividend of 7.01p to be paid on 31 January 2025

·    Dividend yield of 6.2 per cent based on the period end share price (1).

·    As at 30 September 2024 net debt was £70.3 million equivalent to a gearing level of 12.6%.

·    Realisations year to date of £94.5 million.  This represents an increase of 75.3% in comparison to the same period last year.

 

(1)      Calculated as dividends of 7.01p paid on 30 April 2024, 7.01p paid on 31 July 2024, 7.01p paid on 31 October 2024 and 7.01p payable on 31 January 2025, divided by the Company's share price of 455.00p as at 30 September 2024.

 

Manager's Review

 

Introduction

 

As at 30 September 2024 the net assets of the Company were £486.2 million giving a NAV per share of 680.03p, which taking into account the dividend of 7.01p per share paid on 31 July 2024, gives a total return for the third quarter of -1.0%. The total return for the year to date is -0.2%. In the third quarter, there was an adverse influence from currency of around 1.5% as both the dollar and euro were weak against sterling. Underlying valuations are slightly ahead for the year to date. It is worth bearing in mind that the September valuation is largely based on June marks with only around 8% of September valuations included.

 

The Company had net debt of £70.3 million at 30 September 2024. Outstanding undrawn commitments were £192.0 million of which £21.5 million were to funds where the investment period has expired.

 

The dividend for the quarter will be unchanged at 7.01p per share, payable on 31 January 2025 to shareholders on the register on 3 January 2025 with an ex-dividend date of 2 January 2025.

 

New Investments

 

There was only one new investment in the quarter with £5 million committed to Inflexion Enterprise Fund VI, the latest in a series of Inflexion funds focusing on lower mid-market buyouts in the UK and Western Europe.

 

There were some small follow-on investments in our co-investment portfolio which occurred just after the quarter end. £0.9 million was added to the digital payments merchant acquirer Aurora Payment Solutions and £0.5 million was added to police and local offence processing software provider Polaris Software (formerly StarTraq).

 

The funds in the portfolio made a few notable new investments this quarter.

 

HG Saturn 3 called £1.7 million for three investments in Visma (£0.8 million, European and LatAm mission-critical cloud software), Iris (£0.7 million, tax and accounting software) and GGW (£0.1 million, German insurance brokerage and MGA platform).

 

Med Platform II invested £0.8 million in two companies; Jeisys, a South Korean based producer of energy based medical devices and Irrimax Corporation, a US based wound irrigation and anti-microbial solutions provider. Volpi invested £0.8 million in Yaveon (ERP software and consulting provider) and Xalient (software and cybersecurity services provider) and Summa III called £0.5 million for Axion (bioelectronic array and live-cell imaging instruments). Inflexion called £0.5 million for a carve-out of the healthcare division from AIM-listed GlobalData and £0.7 million for DwF, the global legal and professional services firm.

 

In total the third quarter was fairly quiet for new investments with drawdowns totalling just £9.3 million. Total new investment so far this year amounts to £45.2 million which is down on last year by more than 50%.

 

Realisations

 

There were several good exits in the quarter, a number of which have already been reported.

 

The largest exit was the sale of the Kester led co-investment in ATEC. The combined proceeds from both the co-investment, the proportion held in the GCP Europe II fund and the proportion held through The Aurora Fund position was £18.5 million. This represented an excellent  return over the seven-year hold. ATEC is an insurance broker and managing general agent covering caravans, small boats and beach huts. It has grown profits by almost fourfold over the holding period.

 

The Buckthorn-led energy services company Coretrax was fully realised during the quarter with the shares with which its acquirer, Expro, bought the company being sold down successfully realising £10.3 million bringing the total consideration to £13.7 million which at 1.7x cost and 11% IRR is a fair result given the volatile conditions in its sector since the investment was made nearly six years ago.

 

From the funds portfolio there were some excellent further exits.

 

Summa II sold Olink to Thermo Fisher raising £3.6 million. Olink has developed a technology for analysing proteins which is used in human protein biomarker research. The investment achieved a highly creditable 10x cost and an IRR of 67%.

 

Italian fund Nem Imprese made its final exit with the sale of business processing and outsourcing company Kauri yielding £2.1 million.

 

UK fund RJD Fund III exited veterinary education company Improve International returning £1.4 million which represents 3.3x cost and an IRR of 49%.

 

Inflexion Enterprise Fund IV sold pet supplements company Lintbells yielding £1.0 million (5.5x and an IRR of 34%).

 

Astorg VI has made the exits of two companies returning a combined £0.9 million. Acturis, a provider of software for the insurance sector (2.6x, 21% IRR) and Audiotonix the designer and manufacturer of premium professional audio equipment and software (2.6x, 25% IRR). In the case of Acturis, Astorg remains invested in the company through its later funds.

 

In Finland Vaaka II has achieved a remarkable exit of Cloudpermit, a software company serving building permit and land management functions mainly for municipalities. This has been driven by a shift away from predominantly paper-based process to a digital one, increasing the efficiency of the permitting process. £0.7 million was returned which represents 8.7x cost and 53% IRR.

 

As can be noted from the above there remains a strong technology theme in the companies achieving strong exits across the portfolio.

 

Total realisations in the quarter were £42.2 million which brings the year-to-date total to £94.5 million, which compares with £61.8 million for the whole of 2023.

 

Valuation movements

 

The overall valuation movement this quarter is slightly negative. Before taking account of currency movements the underlying portfolio is up by 1.2%. The weakness of both the euro (-1.9%) and the dollar (-5.8%) has resulted in a FX movement in the portfolio of -£10.7 million over the quarter, which has more than offset the gains.

 

The most notable movements in the quarter are as follows. ATEC (+£1.8 million) reflecting its sale at above the latest valuation, Weird Fish (+£1.8 million) due to improved trading, Educa Edtech (+£1.6 million) also trading well and Ambio (+£1.0 million) based on an improved sales multiple. Several of the funds are also up, led by GCP Europe II which holds ATEC (+£0.7 million). Avallon III is up by £0.6 million due to pet food company MPPK trading well. RJD III (+£0.6 million) is up reflecting the sale of Improve International above the holding value as noted above.

 

On the negative side there were a few actual downgrades of note. Breeze Group (formerly Contained Air Solutions) was down by £1.0 million and Bulgarian bike assembler Leader96 was down by £1.5 million. Breeze is in reasonable shape having just completed some useful new additions, with the UK add-on Amercare trading very well in the year to date. Leader96 faces a challenging market which is destocking; however, an agreement with the banks has been reached,  part of the old factory has been sold and reinforcement of management  is under way. Most of the fund positions were slightly up or slightly down, cancelling out one another.

 

Financing

 

The Company had net debt at the end of September of £70.3 million which is well down from £91.3 million at June. This represents gearing of 12.6%. Approximately half of the Company's borrowing facilities are unused with plenty of headroom.

 

Outlook

 

The private equity market internationally has been going through a period of adjustment for most of the last two years. Much higher interest rates and external pressures such as inflation and world events have impacted the dealmaking environment in 2023 and the first half of 2024. The latest trend is more clearly upwards and growth in deal volume and value over 2023 is expected for 2024 as a whole. The clear upswing in realisations across our portfolio confirms this trend. As always business and consumer confidence is an important factor. In many markets, including the US and the UK, 2024 has been an election year and with each of these behind us there is clear scope for a better trend to take root.

 

Private equity is the most interventionist of asset classes where managers can make adjustments as the world around them changes and there is a very strong record of making good returns over the long term irrespective of the background conditions. As we approach the end of 2024, the mood of our investment partners is considerably better than it was earlier in the year and both statistical and anecdotal evidence suggests good grounds for optimism as we finish 2024 and enter 2025. We remain confident that we will continue to build value for Shareholders over the short and longer term.

 

 

Hamish Mair

Investment Manager

Columbia Threadneedle Investment Business Limited

 

 


 

Portfolio Summary

Portfolio Distribution at 30 September 2024

% of Total

30 September 2024

% of Total

31 December 2023

Buyout Funds - Pan European*

11.2

10.5

Buyout Funds - UK

18.7

16.2

Buyout Funds - Continental Europe†

16.7

18.2

Secondary Funds

0.1

0.1

Private Equity Funds - USA

4.4

5.0

Private Equity Funds - Global

2.3

1.7

Venture Capital Funds

4.6

3.7

Direct Investments/Co-investments

42.0

44.6


100.0

100.0

* Europe including the UK.

† Europe excluding the UK.



 

 

 

 

 

 

Ten Largest Holdings

As at 30 September 2024

Total Valuation £'000

% of Total Portfolio

Inflexion Strategic Partners

16,342

2.9

Sigma

14,972

2.7

August Equity Partners V

11,363

2.0

Weird Fish

11,313

2.0

Aliante Equity 3

11,262

2.0

TWMA

10,847

1.9

San Siro

10,127

1.8

Axiom 1

9,942

1.8

Stirling Square Capital II

9,363

1.7

SEP V

9,110

1.6

114,641

20.4

 

Portfolio Holdings

 

Investment

Geographic Focus

 

Total

Valuation

£'000

% of Total Portfolio

 

 

Buyout Funds - Pan European




 

 

Stirling Square Capital II

Europe

9,363

1.7

 

 

Apposite Healthcare III

Europe

9,076

1.6

 

 

Apposite Healthcare II

Europe

8,880

1.6

 

 

F&C European Capital Partners

Europe

8,784

1.6

 

 

MED II

Western Europe

3,286

0.6

 

 

Agilitas 2015 Fund

Northern Europe

2,719

0.5

 

 

Magnesium Capital 1

Europe

2,392

0.4

 

 

Astorg VI

Western Europe

2,231

0.4

 

 

Volpi III

Northern Europe

2,080

0.4

 

 

Verdane XI

Northern Europe

2,041

0.4

 

 

MED Platform II

Global

1,700

0.3

 

 

Wisequity VI

Italy

1,644

0.3

 

 

Summa III

Northern Europe

1,611

0.3

 

 

Agilitas 2020 Fund

Europe

1,261

0.2

 

 

TDR Capital II

Western Europe

1,065

0.2

 

 

ARCHIMED MED III

Global

1,061

0.2

 

 

Verdane Edda III

Northern Europe

943

0.2

 

 

TDR II Annex Fund

Western Europe

921

0.1

 

 

KKA II

Europe

908

0.1

 

 

Inflexion Partnership III

Europe

540

0.1

 

 

Agilitas 2024 HIF

Europe

98

-

 

 

Volpi Capital

Northern Europe

38

-

 

 

Total Buyout Funds - Pan European


62,642

11.2

 

 

 

Buyout Funds - UK




 

 

Inflexion Strategic Partners

United Kingdom

16,342

2.9

 

 

August Equity Partners V

United Kingdom

11,363

2.0

 

 

Axiom 1

United Kingdom

9,942

1.8

 

 

Inflexion Supplemental V

United Kingdom

8,543

1.5

 

 

Inflexion Buyout Fund V

United Kingdom

6,093

1.1

 

 

Apiary Capital Partners I

United Kingdom

5,116

0.9

 

 

Inflexion Buyout Fund VI

United Kingdom

4,811

0.9

 

 

August Equity Partners IV

United Kingdom

4,551

0.8

 

 

Kester Capital II

United Kingdom

3,854

0.7

 

 

FPE Fund II

United Kingdom

3,846

0.7

 

 

Piper Private Equity VI

United Kingdom

3,803

0.7

 

 

FPE Fund III

United Kingdom

3,725

0.7

 

 

Inflexion Partnership Capital II

United Kingdom

3,610

0.6

 

 

Inflexion Enterprise Fund V

United Kingdom

3,206

0.6

 

 

Corran Environmental II

United Kingdom

2,747

0.5

 

 

Inflexion Buyout Fund IV

United Kingdom

2,481

0.4

 

 

Piper Private Equity VII

United Kingdom

2,446

0.4

 

 

Inflexion Supplemental IV

United Kingdom

1,457

0.3

 

 

Inflexion Enterprise Fund IV

United Kingdom

1,439

0.3

 

 

Inflexion Partnership Capital I

United Kingdom

1,078

0.2

 

 

Primary Capital IV

United Kingdom

1,067

0.2

 

 

Horizon Capital 2013

United Kingdom

1,067

0.2

 

 

Kester Capital III

United Kingdom

906

0.2

 

 

RJD Private Equity Fund III

United Kingdom

404

0.1

 

 

Piper Private Equity V

United Kingdom

227

-

 

 

GCP Europe II

United Kingdom

127

-

 

 

August Equity Partners VI

United Kingdom

46

-

 

 

Dunedin Buyout Fund II

United Kingdom

17

-

 

 

Total Buyout Funds - UK


104,314

18.7

 

 





 

 





 

 

Investment

Geographic Focus

 

Total

Valuation £'000

% of Total Portfolio

 

 

Buyout Funds - Continental Europe




 

 

Aliante Equity 3

Italy

11,262

2.0

 

 

Bencis V

Benelux

6,693

1.2

 

 

Avallon MBO Fund III

Poland

6,246

1.1

 

 

DBAG VIII

DACH

5,814

1.0

 

 

DBAG VII

DACH

5,603

1.0

 

 

Vaaka III

Finland

5,234

0.9

 

 

Chequers Capital XVII

France

4,932

0.9

 

 

Capvis III CV

DACH

4,931

0.9

 

 

Verdane Edda

Nordic

4,163

0.8

 

 

Montefiore V

France

4,118

0.7

 

 

Procuritas VI

Nordic

3,799

0.7

 

 

ARX CEE IV

Eastern Europe

3,030

0.5

 

 

Corpfin V

Spain

3,015

0.5

 

 

Procuritas VII

Nordic

2,720

0.5

 

 

Procuritas Capital IV

Nordic

2,472

0.4

 

 

Italian Portfolio

Italy

2,399

0.4

 

 

Capvis IV

DACH

2,092

0.4

 

 

Vaaka IV

Finland

2,073

0.4

 

 

Montefiore IV

France

1,840

0.3

 

 

Aurica IV

Spain

1,514

0.3

 

 

Summa I

Nordic

1,367

0.3

 

 

Summa II

Nordic

1,329

0.2

 

 

Portobello Fund III

Spain

1,204

0.2

 

 

Corpfin Capital Fund IV

Spain

1,065

0.2

 

 

DBAG VIIB

DACH

1,038

0.2

 

 

DBAG VIIIB

DACH

885

0.2

 

 

Chequers Capital XVI

France

675

0.1

 

 

DBAG Fund VI

DACH

583

0.1

 

 

PineBridge New Europe II

Eastern Europe

308

0.1

 

 

Ciclad 5

France

297

0.1

 

 

Procuritas Capital V

Nordic

261

0.1

 

 

Vaaka II

Finland

121

-

 

 

Montefiore Expansion

France

106

-

 

 

Gilde Buyout Fund III

Benelux

89

-

 

 

N+1 Private Equity Fund II

Iberia

87

-

 

 

Capvis III

DACH

50

-

 

 

DBAG Fund V

DACH

5

-

 

 

Herkules Private Equity III

Nordic

4

-

 

 

Total Buyout Funds - Continental Europe


93,424

16.7

 

 





 





 

Secondary Funds

 

 

 

 

 

The Aurora Fund

Europe

330

0.1

 

 

Total Secondary Funds


330

0.1

 

 





 





 





Investment

Geographic Focus

 

Total

Valuation £'000

% of Total Portfolio

 











Total Private Equity Funds - USA

Blue Point Capital IV

North America

7,329

1.3

Camden Partners IV

United States

3,006

0.5

Level 5 Fund II

United States

2,734

0.5

Purpose Brands (Level 5)

United States

2,642

0.5

Graycliff IV

North America

2,594

0.5

Blue Point Capital III

North America

1,946

0.3

Stellex Capital Partners

North America

1,701

0.3

MidOcean VI

United States

1,563

0.3

Graycliff III

United States

980

0.2

Blue Point Capital II

North America

150

-

Total Private Equity Funds - USA

24,645

4.4

 




 




Private Equity Funds - Global




Corsair VI

Global

6,528

1.2

Hg Saturn 3

Global

4,363

0.8

PineBridge GEM II

Global

610

0.1

Hg Mercury 4

Global

508

0.1

F&C Climate Opportunity Partners

Global

459

0.1

AIF Capital Asia III

Asia

108

-

PineBridge Latin America II

South America

55

-

Warburg Pincus IX

Global

9

-

Total Private Equity Funds - Global


12,640

2.3

 

 

Venture Capital Funds




SEP V

United Kingdom

9,110

1.6

MVM V

Global

3,790

0.7

SEP VI

Europe

3,161

0.6

Kurma Biofund II

Europe

2,786

0.5

MVM VI

Global

2,653

0.5

Northern Gritstone

United Kingdom

2,000

0.4

SEP IV

United Kingdom

1,113

0.2

Pentech Fund II

United Kingdom

385

0.1

SEP II

United Kingdom

260

-

Life Sciences Partners III

Western Europe

248

-

SEP III

United Kingdom

60

-

Environmental Technologies Fund

Europe

56

-

Total Venture Capital Funds


25,622

4.6









































Investment

Geographic Focus

 

Total

Valuation £'000

% of Total Portfolio

Direct Investments/Co-investments




Sigma

United States

14,972

2.7

Weird Fish

United Kingdom

11,313

2.0

TWMA

United Kingdom

10,847

1.9

San Siro

Italy

10,127

1.8

Aurora Payment Solutions

United States

9,005

1.6

Utimaco

DACH

8,852

1.6

Cyclomedia

Netherlands

8,751

1.6

Cyberhawk

United Kingdom

8,530

1.5

Breeze Group (CAS)

United Kingdom

8,270

1.5

Amethyst Radiotherapy

Europe

8,118

1.5

Asbury Carbons

North America

6,831

1.2

Velos IoT (JT IoT)

United Kingdom

6,741

1.2

Habitus

Denmark

6,739

1.2

Prollenium

North America

6,227

1.1

CARDO Group

United Kingdom

6,204

1.1

Swanton

United Kingdom

6,199

1.1

Family First

United Kingdom

5,968

1.1

Orbis

United Kingdom

5,799

1.0

Cybit (Perfect Image)

United Kingdom

5,176

0.9

Rosa Mexicano

United States

5,103

0.9

Polaris Software (StarTraq)

United Kingdom

4,840

0.9

AccuVein

United States

4,634

0.8

Educa Edtech

Spain

4,583

0.8

123Dentist

Canada

4,533

0.8

Braincube

France

4,477

0.8

MedSpa Partners

Canada

4,201

0.8

Dotmatics

United Kingdom

4,043

0.7

1Med

Switzerland

3,933

0.7

LeadVenture

United States

3,913

0.7

Walkers Transport

United Kingdom

3,729

0.7

Vero Biotech

United States

2,956

0.5

PathFactory

Canada

2,934

0.5

Omlet

United Kingdom

2,832

0.5

Collingwood Insurance Group

United Kingdom

2,671

0.5

AccountsIQ

Ireland

2,530

0.5

Agilico (DMC Canotec)

United Kingdom

2,516

0.5

GT Medical

United States

2,236

0.4

Neurolens

United States

2,215

0.4

Ambio Holdings

United States

2,041

0.4

Alessa (Tier1 CRM)

Canada

1,947

0.4

OneTouch

United Kingdom

1,861

0.3

Bomaki

Italy

1,466

0.3

Rephine

United Kingdom

1,360

0.2

Avalon

United Kingdom

1,234

0.2

Leader96

Bulgaria

704

0.1

Jollyes

United Kingdom

397

0.1

TDR Algeco/Scotsman

Europe

226

-

Coretrax

United Kingdom

94

-

Total Direct Investments/Co-investments


234,878

42.0

Total Portfolio


558,495

100.0

 

 


 

 

CT PRIVATE EQUITY TRUST PLC

 

Statement of Comprehensive Income for the

nine months ended 30 September 2024 (unaudited)

 

 


 


Revenue

£'000

Capital

£'000

Total

£'000

 

Income




Gains on investments held at fair value

-

83

83

Exchange gains

-

4,443

4,443

Investment income

2,110

-

2,110

Other income

794

-

794

Total income

2,904

4,526

7,430





Expenditure




Investment management fee - basic fee

(365)

(3,284)

(3,649)

Investment management fee - performance fee

-

-

-

Other expenses

(916)

-

(916)

Total expenditure

(1,281)

(3,284)

(4,565)





Profit before finance costs and taxation

1,623

1,242

2,865





Finance costs

(679)

(6,115)

(6,794)

 




Profit/(loss) before taxation

944

(4,873)

(3,929)





Taxation

-

-

-





Profit/(loss) for period/total comprehensive income

944

(4,873)

(3,929)

 




Return per Ordinary Share

1.31p

(6.77)p

(5.46)p

 




 

 

 


 

 

CT PRIVATE EQUITY TRUST PLC

 

Statement of Comprehensive Income for the

nine months ended 30 September 2023 (unaudited)

 


 

 


Revenue

£'000

Capital

£'000

Total

£'000

 

Income




Gains on investments held at fair value

-

14,181

14,181

Exchange gains

-

759

759

Investment income

1,618

-

1,618

Other income

552

-

552

Total income

2,170

14,940

17,110





Expenditure




Investment management fee - basic fee

(354)

(3,187)

(3,541)

Investment management fee - performance fee

-

(5,017)

(5,017)

Other expenses

(816)

-

(816)

Total expenditure

(1,170)

(8,204)

(9,374)





Profit before finance costs and taxation

1,000

6,736

7,736





Finance costs

(336)

(3,026)

(3,362)

 




Profit before taxation

664

3,710

4,374





Taxation

-

-

-





Profit for period/total comprehensive income

664

3,710

4,374

 




Return per Ordinary Share

0.91p

5.09p

6.00p

 




 

 



CT PRIVATE EQUITY TRUST PLC

 

Statement of Comprehensive Income for the

year ended 31 December 2023 (audited)

 

 


 


Revenue

£'000

Capital

£'000

Total

£'000

 

Income




Gains on investments held at fair value

-

25,226

25,226

Exchange gains

-

863

863

Investment income

2,703

-

2,703

Other income

689

-

689

Total income

3,392

26,089

29,481





Expenditure




Investment management fee - basic fee

(474)

(4,263)

(4,737)

Investment management fee - performance fee

-

(4,767)

(4,767)

Other expenses

(1,064)

-

(1,064)

Total expenditure

(1,538)

(9,030)

(10,568)





Profit before finance costs and taxation

1,854

17,059

18,913





Finance costs

(513)

(4,616)

(5,129)

 




Profit before taxation

1,341

12,443

13,784





Taxation

-

-

-





Profit for year/total comprehensive income

1,341

12,443

13,784

 




Return per Ordinary Share

1.84p

17.08p

18.92p

 




 

 



CT PRIVATE EQUITY TRUST PLC

 

Balance Sheet

 

 

 

 

As at 30 September 2024

As at 30 September 2023

As at 31

December

2023

 

(unaudited)

(unaudited)

(audited)

 

£'000

£'000

 £'000

Non-current assets

 

 


Investments at fair value through profit or loss

558,495

589,185

605,603

 




Current assets




Other receivables

3,196

1,551

841

Cash and cash equivalents

22,678

3,995

9,879


25,874

5,546

10,720





Current liabilities




Other payables

(5,144)

(9,036)

(8,121)

Interest-bearing bank loan

(44,222)

(78,477)

(97,109)


(49,366)

(87,513)

(105,230)

Net current liabilities

(23,492)

(81,967)

(94,510)

 




 




Interest-bearing bank loan

(48,760)

-

-

Net assets

486,243

507,218

511,093

 




Equity




Called-up ordinary share capital

739

739

739

Share premium account

2,527

2,527

2,527

Special distributable capital reserve

3,818

10,026

9,597

Special distributable revenue reserve

31,403

31,403

31,403

Capital redemption reserve

1,335

1,335

1,335

Capital reserve

446,421

461,188

465,492

Shareholders' funds

486,243

507,218

511,093





Net asset value per Ordinary Share

680.03p

696.30p

702.50p





 



CT PRIVATE EQUITY TRUST PLC

               

Reconciliation of Movements in Shareholders' Funds

 

 

 

 

 

Nine months ended

30 September

2024

Nine months ended

30 September 2023

Year

ended

31 December 2023

 

(unaudited)

(unaudited)

(audited)

 

£'000

£'000

£'000

Opening shareholders' funds

511,093

517,675

517,675

Buyback of ordinary shares

(5,779)

-

(429)

(Loss)/profit for the period/total

comprehensive income

 

(3,929)

 

4,374

 

13,784

Dividends paid

(15,142)

(14,831)

(19,937)

 

Closing shareholders' funds

 

 

486,243          

 

507,218          

 

511,093

 

 


Notes (unaudited)

 

1.     The unaudited quarterly results have been prepared on the basis of the accounting policies set out in the statutory accounts of the Company for the year ended 31 December 2023.  Earnings for the nine months to 30 September 2024 should not be taken as a guide to the results for the year to 31 December 2024.

 

 

2.     Investment management fee:

 

 

 

Nine months ended

30 September 2024

                              (unaudited)

 

 

Nine months ended

30 September 2023

                             (unaudited)

 

 

Year ended

31 December 2023

                                 (audited)

 

Revenue

£'000

Capital

£'000

Total

£'000

Revenue

£'000

Capital

£'000

Total

£'000

Revenue

£'000

Capital

£'000

Total

£'000

 

 

 

 

 

 

 

 

 

 

Investment management       fee - basic fee

 

365

 

3,284

 

3,649

 

354

 

3,187

 

3,541

 

474

 

4,263

 

4,737

Investment management       fee - performance fee

 

-

 

-

 

-

 

-

 

5,017

 

5,017

 

-

 

4,767

 

4,767

 

 

365

 

3,284

 

3,649

 

354

 

8,204

 

8,558

 

474

 

9,030

 

9,504

 

 

 

 

 

 

 

 

 

 

 

3.     Finance costs:

 

 

 

Nine months ended

30 September 2024

                             (unaudited)

 

 

Nine months ended

 30 September 2023

                             (unaudited)

 

 

Year ended

31 December 2023

(audited)

 

Revenue

£'000

Capital

£'000

Total

£'000

Revenue

£'000

Capital

£'000

Total

£'000

Revenue

£'000

Capital

£'000

Total

£'000

 

 

 

 

 

 

 

 

 

 

Interest payable on bank loans

679

6,115

6,794

336

3,026

3,362

513

4,616

5,129

 

 

 

 

 

 

 

 

 

 

 

4.     Returns and net asset values

 

             Nine months ended

30 September 2024

                        (unaudited)

        Nine months ended

 30 September 2023

                  (unaudited)

                Year ended

31 December 2023

                      (audited)

The returns and net asset values per share are based on the following figures:

 

 

 

 

Revenue Return

£944,000

£664,000

£1,341,000

Capital Return

£(4,873,000)

£3,710,000

£12,443,000

Net assets attributable to shareholders

£486,243,000

£507,218,000

£511,093,000

Number of shares in issue at end of period (excluding shares held in treasury)

71,502,938

72,844,938

72,752,938

Weighted average number of shares in issue during the period

(excluding shares held in treasury)

71,960,967

72,844,938

72,838,637

 

 

 

 

 

 

 

 

5.     The financial information for the nine months ended 30 September 2024, which has not been audited or reviewed by the Company's auditor, comprises non-statutory accounts within the meaning of Section 434 of the Companies Act 2006.  Statutory accounts for the year ended 31 December 2023, on which the auditor issued an unqualified report, have been lodged with the Registrar of Companies.  The quarterly report is available on the Company's website www.ctprivateequitytrust.com

 

Legal Entity Identifier: 2138009FW98WZFCGRN66

 

For more information, please contact:

 

Hamish Mair (Investment Manager)

0131 573 8314

Scott McEllen (Company Secretary)

0131 573 8372

hamish.mair@columbiathreadneedle.com  / scott.mcellen@columbiathreadneedle.com



 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
QRTFEAFMWELSEIF
Ct Private Equity (LSE:CTPE)
Historical Stock Chart
Von Okt 2024 bis Nov 2024 Click Here for more Ct Private Equity Charts.
Ct Private Equity (LSE:CTPE)
Historical Stock Chart
Von Nov 2023 bis Nov 2024 Click Here for more Ct Private Equity Charts.